Department of Interventional Ultrasound, PLA Medical College & Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Guangxi Clinical Research Center for CRC, Department of Gastrointestinal Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.
Hepatology. 2022 Jul;76(1):66-77. doi: 10.1002/hep.32323. Epub 2022 Jan 28.
The study objective was to compare the effectiveness of microwave ablation (MWA) and laparoscopic liver resection (LLR) on solitary 3-5-cm HCC over time.
From 2008 to 2019, 1289 patients from 12 hospitals were enrolled in this retrospective study. Diagnosis of all lesions were based on histopathology. Propensity score matching was used to balance all baseline variables between the two groups in 2008-2019 (n = 335 in each group) and 2014-2019 (n = 257 in each group) cohorts, respectively. For cohort 2008-2019, during a median follow-up of 35.8 months, there were no differences in overall survival (OS) between MWA and LLR (HR: 0.88, 95% CI 0.65-1.19, p = 0.420), and MWA was inferior to LLR regarding disease-free survival (DFS) (HR 1.36, 95% CI 1.05-1.75, p = 0.017). For cohort 2014-2019, there was comparable OS (HR 0.85, 95% CI 0.56-1.30, p = 0.460) and approached statistical significance for DFS (HR 1.33, 95% CI 0.98-1.82, p = 0.071) between MWA and LLR. Subgroup analyses showed comparable OS in 3.1-4.0-cm HCCs (HR 0.88, 95% CI 0.53-1.47, p = 0.630) and 4.1-5.0-cm HCCs (HR 0.77, 95% CI 0.37-1.60, p = 0.483) between two modalities. For both cohorts, MWA shared comparable major complications (both p > 0.05), shorter hospitalization, and lower cost to LLR (all p < 0.001).
MWA might be a first-line alternative to LLR for solitary 3-5-cm HCC in selected patients with technical advances, especially for patients unsuitable for LLR.
本研究旨在比较微波消融(MWA)和腹腔镜肝切除术(LLR)治疗单发 3-5cm HCC 的疗效。
2008 年至 2019 年,12 家医院的 1289 名患者纳入本回顾性研究。所有病变的诊断均基于组织病理学。在 2008-2019 年(每组 335 例)和 2014-2019 年(每组 257 例)两组中,分别使用倾向评分匹配来平衡两组之间的所有基线变量。对于队列 2008-2019,中位随访 35.8 个月,MWA 与 LLR 之间的总生存(OS)无差异(HR:0.88,95%CI 0.65-1.19,p=0.420),MWA 的无病生存(DFS)劣于 LLR(HR 1.36,95%CI 1.05-1.75,p=0.017)。对于队列 2014-2019,MWA 与 LLR 的 OS 相当(HR 0.85,95%CI 0.56-1.30,p=0.460),DFS 接近统计学意义(HR 1.33,95%CI 0.98-1.82,p=0.071)。亚组分析显示,3.1-4.0cm HCC(HR 0.88,95%CI 0.53-1.47,p=0.630)和 4.1-5.0cm HCC(HR 0.77,95%CI 0.37-1.60,p=0.483)之间的 OS 相当。对于两个队列,MWA 与 LLR 的主要并发症发生率相当(均 p>0.05),住院时间更短,费用更低(均 p<0.001)。
随着技术的进步,MWA 可能成为单发 3-5cm HCC 患者的 LLR 一线替代治疗方法,特别是对于不适合 LLR 的患者。